These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7923695)

  • 1. Local drug delivery for the prevention of restenosis. Fact, fancy, and future.
    Lincoff AM; Topol EJ; Ellis SG
    Circulation; 1994 Oct; 90(4):2070-84. PubMed ID: 7923695
    [No Abstract]   [Full Text] [Related]  

  • 2. Local drug delivery systems and prevention of restenosis.
    Brieger D; Topol E
    Cardiovasc Res; 1997 Sep; 35(3):405-13. PubMed ID: 9415284
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-particle-emitting stents radiate enthusiasm in the search for effective prevention of restenosis.
    van der Giessen WJ; Serruys PW
    Circulation; 1996 Nov; 94(10):2358-60. PubMed ID: 8921772
    [No Abstract]   [Full Text] [Related]  

  • 4. Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis.
    Herdeg C; Goehring-Frischholz K; Zuern C; Geisler T; Hartmann U; Hoevelborn T; Haase KK; Gawaz M
    Thromb Res; 2008; 123(2):236-43. PubMed ID: 18452977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of brachytherapy for the prevention of restenosis.
    Lee DP; Lo S; Forster K; Yeung AC; Oesterle SN
    Vasc Med; 1999; 4(4):257-68. PubMed ID: 10613631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary artery disease treatment in the catheterization laboratory: the promise of an evolving new pharmaco-mechanical approach. Introduction.
    Lepor NE; Rogers CD
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S1-3. PubMed ID: 12508806
    [No Abstract]   [Full Text] [Related]  

  • 7. [Local drug administration systems, preclinical and clinical use: perspectives and limitations].
    Gonschior P; Wilensky R; March K; Höfling B
    Z Kardiol; 1996 Mar; 85(3):155-65. PubMed ID: 8659193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some thoughts on the present and future of coronary artery stenting.
    De Feyter PJ; Ruygrok PN; Mills P
    Heart; 1996 Jun; 75(6):546-8. PubMed ID: 8697154
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost.
    Alt E; Haehnel I; Beilharz C; Prietzel K; Preter D; Stemberger A; Fliedner T; Erhardt W; Schömig A
    Circulation; 2000 Mar; 101(12):1453-8. PubMed ID: 10736292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery.
    Gradus-Pizlo I; Wilensky RL; March KL; Fineberg N; Michaels M; Sandusky GE; Hathaway DR
    J Am Coll Cardiol; 1995 Nov; 26(6):1549-57. PubMed ID: 7594084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of instant restenosis after coronary angioplasty by implantation of rapamycin-coated stents].
    Hansen PR; Abildgaard U; Galløe AM; Kassis E
    Ugeskr Laeger; 2001 Mar; 163(12):1714. PubMed ID: 11284414
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of biodegradable stents.
    Tanguay JF; Zidar JP; Phillips HR; Stack RS
    Cardiol Clin; 1994 Nov; 12(4):699-713. PubMed ID: 7850839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
    Lima VC; Mattos LA; Caramori PR; Perin MA; Mangione JA; Machado BM; Coelho WM; Bueno RR
    Arq Bras Cardiol; 2006 Oct; 87(4):e162-7. PubMed ID: 17128305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug-eluting stents under study.
    Mitka M
    JAMA; 2007 May; 297(19):2064-7. PubMed ID: 17507335
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanisms and prevention of restenosis after coronary angioplasty].
    Drechsel S; Bertel O; Lafont A
    Schweiz Med Wochenschr; 1998 Mar; 128(13):497-507. PubMed ID: 9583101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on drug-eluting stents for prevention of restenosis.
    Lee CH; Tan HC; Lim YT
    Asian Cardiovasc Thorac Ann; 2006 Feb; 14(1):75-82. PubMed ID: 16432127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCT Daily: safety profile of drug-eluting stents similar to bare-metal stents: lower restenosis rates associated with DES.
    Kahn J
    J Interv Cardiol; 2007 Feb; 20(1):30-1. PubMed ID: 17300395
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiotherapy to inhibit coronary restenosis: kind of a light at the end of the tunnel?
    Teirstein PS
    Eur Heart J; 1998 Jan; 19(1):3-6. PubMed ID: 9503167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.